Dinapsoline

In Dinapsoline's article, we will be exploring a topic that has generated interest and debate in various spheres of society. Over time, Dinapsoline has proven to be a figure/theme/date of relevance and importance, with multiple facets and aspects that deserve to be explored in depth. From its impact on popular culture to its implications in the social sphere, Dinapsoline has been the subject of analysis and reflection by experts and fans alike. During this article, we will closely examine different aspects related to Dinapsoline, with the aim of providing a comprehensive and enriching perspective on this topic.

Dinapsoline
Clinical data
ATC code
  • none
Identifiers
  • 8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-naphisoquinoline
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H15NO2
Molar mass253.301 g·mol−1
3D model (JSmol)
  • Oc1c3c(ccc1O)4c2c(cccc2C3)CNC4
  • InChI=1S/C16H15NO2/c18-14-5-4-11-12(16(14)19)6-9-2-1-3-10-7-17-8-13(11)15(9)10/h1-5,13,17-19H,6-8H2/t13-/m0/s1 ☒N
  • Key:ZQTSNGJHMUKLOM-ZDUSSCGKSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Dinapsoline is a drug developed for the treatment of Parkinson's disease,[1] that acts as a selective full agonist at the dopamine D1 receptor.[2][3][4][5]

References

  1. ^ Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, Taber MT (February 2001). "Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease". The Journal of Pharmacology and Experimental Therapeutics. 296 (2): 338–44. PMID 11160615.
  2. ^ Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE (January 1996). "9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naphisoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore". Journal of Medicinal Chemistry. 39 (2): 549–55. doi:10.1021/jm950707+. PMID 8558526.
  3. ^ Sit SY, Xie K, Jacutin-Porte S, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Wong H, Zhu J, Krishnananthan S, Gao Q, Verdoorn T, Johnson G (August 2002). "(+)-Dinapsoline: an efficient synthesis and pharmacological profile of a novel dopamine agonist". Journal of Medicinal Chemistry. 45 (17): 3660–8. doi:10.1021/jm0101545. PMID 12166939.
  4. ^ Sit SY, Xie K, Jacutin-Porte S, Boy KM, Seanz J, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Verdoorn T, Johnson G, Nichols DE, Mailman RB (February 2004). "Synthesis and SAR exploration of dinapsoline analogues". Bioorg. Med. Chem. 12 (4): 715–34. doi:10.1016/j.bmc.2003.11.015. PMID 14759732.
  5. ^ Gleason SD, Witkin JM (May 2006). "Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine". Psychopharmacology. 186 (1): 25–31. doi:10.1007/s00213-006-0342-2. PMID 16575553. S2CID 2159983.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.